Angiotenzin

(Preusmjereno sa stranice Angiotenzin II)
edit

Angiotenzin je protein koji se pod uticajem enzima renina daje angiotenzin I, čije se proteinsko tijelo sastoji od 10 aminokiselina.[1]

Angiotenzin (inhibitor seprin peptidaze, klasa A, član 8)

Modeli angiotenzina I (levo) i II (desno) iz PDB 1N9U i PDB 1N9V.
Identifikatori
SimboliAGT; ANHU; SERPINA8
Vanjski IDOMIM106150 MGI87963 HomoloGene14 GeneCards: AGT Gene
Pregled RNK izražavanja
podaci
Ortolozi
VrstaČovekMiš
Entrez18311606
EnsemblENSG00000135744ENSMUSG00000031980
UniProtP01019Q3UTR7
Ref. Sekv. (iRNK)NM_000029NM_007428
Ref. Sekv. (protein)NP_000020NP_031454
Lokacija (UCSC)Chr 1:
228.9 - 228.92 Mb
Chr 8:
127.44 - 127.46 Mb
PubMed pretraga[1][2]

Angiotenzin se proizvodi u jetri, a cirkuliše u krvnoj plazmi čovjeka. On je bitan faktor kod regulacije krvnog pritiska, jer je direktni činilac sistema renin-angiotenzin-aldosteron (RAAS).[2]

Kod čovjeka, angiotenzin se sastoji iz 485 aminokiselina. NJegov gen leži na dugom kraku hromozoma 1.

Reference

uredi
  1. Donald Voet, Judith G. Voet (2005). Biochemistry (3 izd.). Wiley. ISBN 978-0-471-19350-0. 
  2. Bruce Alberts, Alexander Johnson, Julian Lewis, Martin Raff, Keith Roberts, Peter Walter (2002). Molecular Biology of the Cell. New York: Garlard Science. ISBN 0-8153-3218-1. 

Literatura

uredi
  • de Gasparo M, Catt KJ, Inagami T, "et al." (2000). „International union of pharmacology. XXIII. The angiotensin II receptors”. Parmacol Rev. 52 (3): 415-472. PMID 10977869. 
  • Brenner & Rector's The Kidney, 7th ed., Saunders, 2004.
  • Mosby's Medical Dictionary, 3rd Ed., CV Mosby Company, 1990.
  • Review of Medical Physiology, 20th Ed., William F. Ganong, McGraw-Hill, 2001.
  • Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed., Burton David Rose & Theodore W. Post McGraw-Hill, 2001
  • Lees KR, MacFadyen RJ, Doig JK, Reid JL (1993). „Role of angiotensin in the extravascular system”. Journal of human hypertension 7 Suppl 2: S7–12. PMID 8230088. 
  • Weir MR, Dzau VJ (2000). „The renin-angiotensin-aldosterone system: a specific target for hypertension management”. Am. J. Hypertens. 12 (12 Pt 3): 205S–213S. DOI:10.1016/S0895-7061(99)00103-X. PMID 10619573. 
  • Berry C, Touyz R, Dominiczak AF, et al. (2002). „Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide”. Am. J. Physiol. Heart Circ. Physiol. 281 (6): H2337–65. PMID 11709400. 
  • Sernia C (2002). „A critical appraisal of the intrinsic pancreatic angiotensin-generating system”. JOP 2 (1): 50-5. PMID 11862023. 
  • Varagic J, Frohlich ED (2003). „Local cardiac renin-angiotensin system: hypertension and cardiac failure”. J. Mol. Cell. Cardiol. 34 (11): 1435-42. DOI:10.1006/jmcc.2002.2075. PMID 12431442. 
  • Wolf G (2006). „Role of reactive oxygen species in angiotensin II-mediated renal growth, differentiation, and apoptosis”. Antioxid. Redox Signal. 7 (9-10): 1337-45. DOI:10.1089/ars.2005.7.1337. PMID 16115039. 
  • Cazaubon S, Deshayes F, Couraud PO, Nahmias C (2006). „[Endothelin-1, angiotensin II and cancer]”. Med Sci (Paris) 22 (4): 416-22. PMID 16597412. 
  • Ariza AC, Bobadilla NA, Halhali A (2007). „[Endothelin 1 and angiotensin II in preeeclampsia]”. Rev. Invest. Clin. 59 (1): 48-56. PMID 17569300. 

Spoljašnje veze

uredi